Skip to main content
. Author manuscript; available in PMC: 2010 Sep 1.
Published in final edited form as: J Neuropathol Exp Neurol. 2009 Sep;68(9):994–1005. doi: 10.1097/NEN.0b013e3181b44ed8

Figure 1.

Figure 1

Localization of leucine-rich repeat kinase 2 (LRRK2) in the brains of Parkinson disease (PD) and dementia with Lewy bodies (DLB) cases. (A) The location of peptides recognized by 3 LRRK2-specific polyclonal antibodies are shown aligned to the protein domain structure of LRRK2. (B-G) LRRK2 immunoreactivity in the core (arrowheads) and its outer rim (arrows) of brainstem-type Lewy bodies (LBs) in the substantia nigra pars compacta (B, E), locus coeruleus (C, D, G) or dorsal vagal nucleus (F) of PD (B, C, E, F) or DLB (D, G) brains. (H, I) Double immunolabeling for LRRK2 (brown) and phosphorylated α-synuclein (blue) shows colocalization of LRRK2 with α-synuclein-positive brainstem-type LBs (dark brown). (J) LRRK2 immunohistochemistry in the amygdala of a DLB brain; LRRK2-positive enlarged granules are observed within the cytoplasm of neurons (arrowheads). Scale bars = 20 μm.